Triptorelin Treatment Guide: Trelstar, Triptodur, Decapeptyl, Cost and Provider Paths
In the United States, Triptorelin is an FDA-approved peptide therapy. Advanced prostate cancer; central precocious puberty; endometriosis; preoperative treatment of uterine leiomyomata
This content was medically reviewed by Sarah Chen, MD, Board-Certified in Endocrinology, Diabetes, and Metabolism.
Triptorelin is a synthetic decapeptide agonist of gonadotropin-releasing hormone (GnRH), approved by the FDA for advanced prostate cancer, central precocious puberty, and endometriosis. It suppresses sex hormone production through pituitary desensitization.
Approved Product Paths
Branded triptorelin pathway. Advanced prostate cancer; central precocious puberty; endometriosis; preoperative treatment of uterine leiomyomata
Branded triptorelin pathway. Advanced prostate cancer; central precocious puberty; endometriosis; preoperative treatment of uterine leiomyomata
Branded triptorelin pathway. Advanced prostate cancer; central precocious puberty; endometriosis; preoperative treatment of uterine leiomyomata
- •First-line androgen deprivation therapy for prostate cancer
- •Halts progression of central precocious puberty in children
- •Treats endometriosis and uterine fibroids via ovarian suppression
- •Used in fertility preservation and assisted reproduction protocols
- •Initial testosterone flare (first 1-2 weeks; may worsen bone pain)
- •Hot flashes, decreased libido, erectile dysfunction
- •Bone mineral density loss (osteoporosis risk with long-term use)
- •Metabolic changes (increased fat mass, insulin resistance)
How Triptorelin Works
Triptorelin is a synthetic decapeptide GnRH (gonadotropin-releasing hormone) agonist. Chronic administration downregulates GnRH receptors on pituitary gonadotrophs, suppressing LH and FSH secretion and inducing a medical castration state.
Triptorelin is a potent GnRH superagonist. Acute administration stimulates LH and FSH release (flare effect), but continuous exposure causes desensitization and downregulation of GnRH receptors. After 1-2 weeks, LH and FSH fall to castrate levels.
In men, suppressed LH eliminates testicular testosterone production, reducing serum testosterone to castrate levels (<50 ng/dL). This is the basis for prostate cancer treatment.
In women, suppressed FSH and LH arrest ovarian steroidogenesis, producing a hypoestrogenic state. This is used for endometriosis, uterine fibroids, precocious puberty, and assisted reproduction protocols.
In children with central precocious puberty, triptorelin halts pubertal progression by suppressing the hypothalamic-pituitary-gonadal axis.
The depot formulations use microspheres (1-month, 3-month, 6-month) to provide sustained release and avoid the need for frequent injections.
The initial testosterone flare in men can cause tumor flare (bone pain, urinary obstruction) in metastatic prostate cancer. Antiandrogens are typically given for the first 2-4 weeks to block this effect.
Clinical Trial Evidence
Prostate cancer trials
PMID: 7685252- >95% achieved castrate testosterone levels within 3-4 weeks
- Testosterone suppression maintained for duration of therapy
- 3-month and 6-month depot formulations showed equivalent suppression to monthly
- Quality of life comparable to other GnRH agonists
Endometriosis trials
PMID: 7952477- Dysmenorrhea reduced by >60% in treated patients
- Pelvic pain scores improved significantly vs placebo
- Laparoscopic evaluation showed lesion regression in ~50%
- Add-back therapy (estrogen/progestin) reduced bone loss without compromising efficacy
Dosing & Administration
- •Administered by healthcare professional via deep intramuscular injection
- •Use gluteal muscle; rotate sites
- •For first 2-4 weeks, give antiandrogen (bicalutamide) to prevent tumor flare
- •Monitor testosterone every 3 months (target <50 ng/dL)
- •Course limited to 6 months due to bone loss risk
- •Consider add-back therapy (norethindrone acetate 5 mg daily or conjugated estrogens 0.625 mg + medroxyprogesterone 5 mg) to reduce bone loss and vasomotor symptoms
- •Monitor bone density if repeat courses considered
Side Effect Profile
Men (androgen deprivation)
Most common side effect
Expected with castrate testosterone
Expected
Bone density declines 2-5% per year; monitor DEXA
Weight gain, insulin resistance, dyslipidemia
Common
Women (hypoestrogenism)
Most common
May affect sexual function
Mood changes, irritability
3-8% BMD loss in 6 months without add-back therapy
General
IM injection discomfort
Transient
Contraindications & Warnings
Do Not Use
- Pregnancy (will cause fetal harm)
- Breastfeeding
- Undiagnosed vaginal bleeding (women)
- Hypersensitivity to triptorelin or GnRH analogs
Important Warnings
- Tumor flare: initial testosterone surge in men may worsen bone pain, urinary obstruction, or spinal cord compression. Give antiandrogen prophylaxis for first 2-4 weeks.
- Bone loss: significant with long-term use in men and women. DEXA monitoring and calcium/vitamin D supplementation recommended.
- Cardiovascular risk: androgen deprivation therapy associated with increased risk of diabetes, myocardial infarction, and stroke in some studies.
- QT prolongation: avoid in patients with congenital long QT syndrome or electrolyte abnormalities.
- Pseudotumor cerebri reported in children with precocious puberty (rare).
Drug Interactions
| Drug | Interaction | Severity | Mechanism |
|---|---|---|---|
| Antiandrogens (bicalutamide) | Synergistic (intentional) | minor | Antiandrogen blocks initial testosterone flare during first 2-4 weeks |
| Drugs prolonging QT interval | Additive QT risk | major | Androgen deprivation may prolong QT; avoid combination |
| Estrogens/progestins | May reduce efficacy without add-back protocol | moderate | Add-back therapy carefully dosed to reduce side effects without restoring ovarian function |
Monitoring Requirements
- Testosterone every 3 months (prostate cancer; target <50 ng/dL)
- PSA every 3 months (prostate cancer)
- DEXA bone density annually
- Fasting glucose and lipid panel every 6 months
- Cardiovascular risk assessment annually
- Women: bone density after 6-month course; assess need for add-back
How Triptorelin Compares
All GnRH agonists produce similar castrate levels
Multiple depot options for both
GnRH antagonists avoid flare; preferred for high-risk metastatic disease
Triptorelin 6-month depot reduces injection burden
Medical castration is reversible; surgery is not
Evidence Quality Assessment
Is Triptorelin Right for You?
Ideal Candidates
- Men with locally advanced or metastatic prostate cancer requiring androgen deprivation
- Women with moderate-severe endometriosis refractory to other therapy
- Children with central precocious puberty
- Patients who prefer reversible medical castration over orchiectomy
- Patients seeking longer depot intervals (3 or 6 months) to reduce clinic visits
Avoid
- Patients with metastatic prostate cancer and impending spinal cord compression (consider degarelix instead to avoid flare)
- Women with osteoporosis or high fracture risk
- Patients with significant cardiovascular disease
- Pregnancy or planned pregnancy
Use With Caution
- Diabetes or metabolic syndrome
- Osteoporosis or osteopenia
- Cardiovascular disease
- QT prolongation risk
- Depression or mood disorders
Cost & Insurance Deep Dive
Savings Programs
Cost-Effectiveness Notes
- •Standard of care for prostate cancer; cost justified by survival benefit
- •Longer depot intervals reduce administration costs and improve adherence
- •Generic GnRH agonists available but depot formulations remain branded
- •Androgen deprivation is lifelong for metastatic disease; cumulative cost is significant
Ready to find a triptorelin provider?
Use the provider matcher to compare treatment paths by state, coverage, budget, urgency, and intake mode before committing to a prescribing workflow.
Find a triptorelin providerWellness Support Products
Tools and supplements that support overall health and vitality.
Smart WiFi Body Scale
Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.
Digital Kitchen Food Scale
Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.
Protein Shaker Bottle Set
Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Recommended Reading
Books covering peptide science, longevity research, and biohacking frameworks.
The Peptide Protocols
Comprehensive reference for peptide mechanisms, dosing research, and clinical applications.
Boundless by Ben Greenfield
Covers peptides, nootropics, hormones, and longevity strategies in an optimization framework.
Lifespan by David Sinclair
Evidence-based deep-dive into aging science, directly relevant to longevity peptide research.
The Longevity Paradox
Gut-centric aging research with diet and supplementation protocols for extending healthspan.
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Triptorelin FAQ
Sources
- 1. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.Eur Urol • 2014Claim type: clinicalView source →
- 2. FDA Information on TriptorelinFDA • 2026Claim type: regulatoryView source →
This content is for informational purposes only and does not constitute medical advice.